Amylin Analogs: A Guide to Pramlintide, Cagrilintide, and the Amylin-GLP-1 Axis

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meal-associated glucose and incretin signals. The co-secretion ratio is approximately 100:1 insulin:amylin, meaning amylin reaches the circulation alongside insulin at low nanomolar concentrations and acts over minutes to shape the postprandial response. Native amylin has a plasma half-life of roughly 13 minutes — short enough to track meal-to-meal glycemic regulation but requiring either continuous secretion or engineered analogs for therapeutic use.

Amylin acts on amylin receptors, which are not standalone GPCRs but rather heterodimeric complexes formed between the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3), producing AMY1, AMY2, and AMY3 receptor subtypes. These receptors are expressed in the area postrema and nucleus tractus solitarius of the brainstem — circumventricular regions where peripheral peptides can act on CNS tissue without crossing the blood-brain barrier. Activation reduces food intake, slows gastric emptying through vagal-efferent modulation, and suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner.

A less benign aspect of amylin biology is its propensity for amyloid aggregation. Pathological aggregation of IAPP into amyloid fibrils within pancreatic islets is a near-universal feature of advanced type 2 diabetes, implicated in beta-cell dysfunction and death through inflammasome activation, ER stress, and membrane disruption. Therapeutic amylin analogs are engineered to resist this aggregation — native amylin's tendency to form amyloid makes it unsuitable as a drug even setting aside its short half-life.

Pramlintide, marketed under the brand name Symlin, is a synthetic 37-amino-acid peptide engineered as a non-aggregating analog of human amylin. Three proline substitutions — replacing the amino acids in positions 25, 28, and 29 of native amylin — prevent amyloid fibril formation while preserving receptor binding and biological activity. Pramlintide received FDA approval in 2005 as an adjunct to mealtime insulin for adults with type 1 and type 2 diabetes, making it the first non-insulin therapy approved for type 1 disease.

Clinically, pramlintide is administered by subcutaneous injection immediately before major meals, with titrated dosing to minimize nausea. Pivotal trials demonstrated HbA1c reductions of roughly 0.4–0.7% and body weight reductions of 1.7 kg in type 1 diabetes and up to 3.7 kg in type 2 diabetes over 16–52 weeks versus placebo. The mechanism mirrors endogenous amylin: delayed gastric emptying blunts the postprandial glucose rise, glucagon suppression reduces hepatic glucose output during meals, and satiety signaling reduces caloric intake. Nausea is the primary tolerability hurdle and is dose-dependent and typically improves within weeks of titration.

Commercially, pramlintide has had a complicated trajectory. It was voluntarily withdrawn from the US market by AstraZeneca around 2020, reportedly due to commercial rather than safety reasons, and is no longer available through standard pharmacy channels as of 2026. Compounding pharmacy availability varies by jurisdiction. The clinical and mechanistic relevance persists — pramlintide remains the only FDA-approved amylin analog in recent history, and its pharmacology underpins the next-generation compound cagrilintide.

Cagrilintide is a synthetic amylin analog developed by Novo Nordisk and engineered for once-weekly subcutaneous administration. It is built on a 37-amino-acid backbone similar to pramlintide's with three key amino acid substitutions (N14E, V17R, P37Y) that improve metabolic stability, and N-terminal acylation with a C20 eicosanedioic fatty diacid via a gamma-glutamic acid linker that enables albumin binding. The combined modifications extend plasma half-life to approximately 7–8 days — the pharmacokinetic profile required for weekly dosing.

At the amylin receptor, cagrilintide activates the CTR/RAMP heterodimers in the area postrema and nucleus tractus solitarius, producing the canonical amylin signature: satiety signaling that reduces meal size, delayed gastric emptying that blunts post-meal glucose excursions, and glucagon suppression that reduces hepatic glucose output during meals. The once-weekly dosing also smooths the nausea profile relative to mealtime pramlintide — slower absorption and more sustained exposure appear to produce less severe dose-dependent nausea at comparable receptor-engagement levels.

The Phase 2 CALM trial of cagrilintide monotherapy reported 10.8% body weight reduction at the highest 4.5 mg weekly dose at 26 weeks, versus 3.0% for placebo. Phase 3 development has concentrated on the combination product CagriSema — cagrilintide plus semaglutide — rather than cagrilintide monotherapy. Regulatory submission for cagrilintide alone has not been announced as of 2026; its commercial trajectory is tied to the CagriSema program, which is where the most consequential recent trial data have emerged.

Understanding the amylin class benefits from contrast with the GLP-1 receptor agonist class, and lixisenatide provides an unusually direct comparison. Lixisenatide was a once-daily short-acting GLP-1 receptor agonist (brand names Adlyxin in the US, Lyxumia elsewhere) derived from exendin-4, with a C-terminal hexalysine extension that conferred DPP-4 resistance and modified receptor binding. Its plasma half-life was approximately 2–3 hours, short enough that its glucose-lowering profile was dominated by a pronounced and transient inhibition of gastric emptying concentrated around the postprandial period.

This short-acting profile mattered clinically. In the GetGoal clinical program, lixisenatide produced HbA1c reductions of 0.7–1.0% and modest weight loss of 1–2 kg, with particular efficacy in controlling 2-hour postprandial glucose when combined with basal insulin. The ELIXA cardiovascular outcomes trial — the first CVOT completed for any GLP-1 agonist — demonstrated cardiovascular safety (noninferiority) but not superiority for MACE versus placebo. Commercially, lixisenatide was withdrawn from the US market by Sanofi in January 2023, reflecting competition from longer-acting GLP-1 agents with broader efficacy profiles.

The comparison with pramlintide is instructive. Both were short-acting mealtime agents that emphasized postprandial glycemic control via gastric emptying inhibition. Both were eclipsed commercially by longer-acting weekly compounds in their respective classes. And both illustrate a drug-class principle that has shaped metabolic peptide development: sustained receptor engagement through weekly dosing generally produces larger weight-loss and glycemic effects than mealtime dosing, at the cost of losing the precise postprandial-glucose control that short-acting agents can provide.

Amylin and GLP-1 both reduce food intake and improve glycemic control, and their effects on weight loss overlap substantially in patients — yet they act on different receptors in different brainstem nuclei, and their neural circuits are at least partially non-overlapping. This is the pharmacological rationale for combining them.

GLP-1 receptor agonists act at the GLP-1 receptor — a class B GPCR — in pancreatic beta cells (augmenting glucose-dependent insulin secretion), pancreatic alpha cells (suppressing glucagon), gastric smooth muscle (slowing emptying), and multiple CNS sites including the arcuate nucleus and area postrema. Amylin analogs act at the CTR/RAMP heterodimeric amylin receptors in the area postrema and nucleus tractus solitarius, producing satiety via neural pathways that are anatomically and transcriptionally distinct from GLP-1-responsive neurons.

The practical consequence is that amylin and GLP-1 produce satiety signals that are additive rather than substitutive. In preclinical models, combining amylin and GLP-1 receptor agonists produces weight loss greater than either alone at matched exposure. This is the pharmacological foundation for CagriSema — the Phase 3 combination of cagrilintide and semaglutide — and for broader industry interest in dual amylin/GLP-1 agonists that combine both activities in a single peptide molecule.

CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, both administered once weekly by subcutaneous injection. It pairs the long-acting amylin receptor agonist with the most commercially successful GLP-1 receptor agonist to date, exploiting the non-overlapping neural pathways described in the previous section. The Phase 3 REDEFINE 1 trial reported 22.7% mean body weight loss at 68 weeks in adults with obesity — exceeding the 14.8% weight loss observed in parallel semaglutide-alone trials in similar populations.

If those numbers hold in full regulatory review, CagriSema will be among the most effective weight-loss pharmacotherapies ever approved. The tolerability profile is consistent with the amylin and GLP-1 classes — nausea, vomiting, diarrhea, and decreased appetite dominate adverse events, typically mild to moderate and dose-titration-responsive. Cardiovascular outcome data are pending. Regulatory submission is anticipated following completion of the Phase 3 REDEFINE program; as of 2026, CagriSema is not FDA-approved and is not commercially available through standard or compounding channels.

The broader industry context is worth noting. Multiple companies are developing dual and triple agonists that combine GLP-1 with one or more of: amylin (cagrilintide, amycretin), GIP (tirzepatide-style), glucagon (retatrutide), and PYY. The common thread is additive neural circuit engagement: each hormone signals satiety or glycemic control through at least partially non-overlapping pathways, so combinations produce effects larger than any single mechanism alone. CagriSema is the most mature example of this combination strategy as applied to amylin plus GLP-1.

Amylin analogs have a distinctive safety profile shaped by their mechanism. Amylin itself does not cause hypoglycemia — it suppresses glucagon in a glucose-dependent manner and signals satiety rather than directly lowering blood glucose. The clinically important hypoglycemia risk with pramlintide arose from combination with mealtime insulin: by slowing gastric emptying and reducing postprandial glucose rise, pramlintide could unmask inappropriate insulin dosing, producing severe hypoglycemia when mealtime insulin was not reduced at initiation. Pramlintide prescribing guidance therefore included reducing mealtime insulin by 50% at initiation and titrating dose cautiously.

Nausea is the most common adverse event across the amylin class. It is dose-dependent, typically mild to moderate, and improves with continued dosing. Long-acting cagrilintide produces less severe nausea per unit of receptor engagement than short-acting pramlintide, likely due to smoother pharmacokinetics — sudden peaks in receptor activation appear to drive the worst nausea episodes. CagriSema nausea is numerically higher than semaglutide monotherapy, consistent with added amylin-receptor exposure, but remains in the range typically tolerable with titration.

Patient-selection considerations matter in contexts where amylin analogs are used outside diabetes management. Pramlintide is not approved for weight loss in the absence of insulin-treated diabetes, and its US market withdrawal removes standard prescribing channels regardless. Cagrilintide is not approved for any indication as of 2026; off-label use is limited by availability. CagriSema will, if approved, need similar patient-selection care — the combination's GI side-effect profile and the long duration of exposure favor careful titration and monitoring, particularly in older or frail patients. Amylin analogs are pharmacologically potent agents whose best use cases — like the GLP-1 class before them — require clinical judgment that goes beyond the basic indication label.